Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thoracic radiotherapy plus durvalumab in elderly or frail stage III NSCLC patients unfit for chemotherapy
2019-002192-33Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Oct 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Treatment-related pneumonitis grade 3 or higher. Started Oct 2019; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-002192-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002192-33.